KMC ends agreement with Israeli Optimedic:
This article was originally published in Clinica
Optimedic Medical Technologies, an Israeli developer of carbon dioxide lasers for medical applications, is looking for a US distributor, following KMC Systems' termination of its manufacturing and distribution agreement with the Or-Yehuda-based Optimedic. While Optimedic claims that KMC failed to achieve any sales of its PenduLaser in the past two years, it adds that KMC "has raised some financial demands - regarding the termination of the agreement". Optomedics' products are designed for small clinics and doctors' offices.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.